Digital therapeutics (DTx) company Pear Therapeutics may be heading for a new lease of life, if a plan by former chief executive Corey McCann pays off.
As Pear Therapeutics’ financial situation forces the company into bankruptcy, Ben Hargreaves takes a look at whether this is just a blip on the road for digital therapeutics, or a sign of d
The burgeoning field of digital therapeutics was struck a blow today when Boston-based Pear Therapeutics, one of the pioneers of the space, declared Chapter 11 bankruptcy.
Pear Therapeutics already has three FDA-approved prescription digital therapeutics (DTx) on the market – but it seems that isn’t enough to ensure a stable financial positi
Addiction treatment specialist Spero Health has expanded an agreement to use Pear Therapeutics’ prescription digital therapeutics (DTx) in its network of US clinics.
The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the are
MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio